#IMTX

StockTitan

@stocktitan.net

1 week ago

Immatics Announces Full Year 2025 Financial Results and Business Update Immatics (NASDAQ: IMTX) reported full-year 2025 results and a business update on March 5, 2026, highlighting clinical progress across its PRAME franchise and financials. Cash and other financial assets totaled $551.4 million as of December 31, 2025, with cash reach extended into 2028.Key clinical timelines include SUPRAME Phase 3 interim and final analyses expected in 2026, BLA submission in 1H 2027, and commercial launch in 2H 2027. The company completed a $125 million public offering on December 8, 2025.

#IMTX Immatics Announces Full Year 2025 Financial Results and Business Update

www.stocktitan.net/news/IMTX/immatics-annou...

Fred Hutch

@fredhutch.org

2 months ago

Fred Hutch is recruiting a full-time Associate Professor in the Translational Science & Therapeutics Division. We are seeking candidates with expertise in hematopathology and molecular pathology, and interest in #HSCT, #IMTX and lymphoid neoplasms. Apply: https://apply.interfolio.com/178338

Fred Hutch

@fredhutch.org

2 months ago

Fred Hutch is recruiting a full-time Associate Professor in the Translational Science & Therapeutics Division. We are seeking candidates with expertise in hematopathology and molecular pathology, and interest in #HSCT, #IMTX and lymphoid neoplasms. Apply: https://apply.interfolio.com/178338

Fred Hutch

@fredhutch.org

3 months ago

Fred Hutch is recruiting a full-time Associate Professor in the Translational Science & Therapeutics Division. We are seeking candidates with expertise in hematopathology and molecular pathology, and interest in #HSCT, #IMTX and lymphoid neoplasms. Apply: https://apply.interfolio.com/178338

StockTitan

@stocktitan.net

3 months ago

Immatics Announces $125 Million Underwritten Offering Immatics (NASDAQ: IMTX) agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering, generating expected gross proceeds of $125 million before underwriting discounts and offering expenses.The offering is expected to close on December 8, 2025, subject to customary closing conditions; a registration statement was declared effective on April 3, 2025. Jefferies, Leerink Partners and Cantor are joint book‑running managers. The shares are being offered only by prospectus supplement and accompanying prospectus.

#IMTX Immatics Announces $125 Million Underwritten Offering

www.stocktitan.net/news/IMTX/immatics-annou...

StockTitan

@stocktitan.net

3 months ago

#IMTX Immatics Announces Third Quarter 2025 Financial Results and Business Update

www.stocktitan.net/news/IMTX/immatics-annou...

StockTitan

@stocktitan.net

4 months ago

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit with more mature data: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at

#IMTX Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

www.stocktitan.net/news/IMTX/immatics-highl...

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Small-cap stocks with improving money flow, Tue Sept 23rd - #SAVA #PDYN #NUTX #IMTX #GSIT #FAT #EM #CYCN #BHST #ATRA #VEL #SPI - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

7 months ago

Promising Melanoma Treatment: Immatics' Cell Therapy Delivers 12-Month Duration Response in Phase 1b Trial Anzu-cel therapy demonstrates 56% response rate in metastatic melanoma patients with 12.1-month duration. Phase 3 trial progressing with $560M cash runway into 2027. See full results.

#IMTX Immatics Announces Second Quarter 2025 Financial Results and Business Update

www.stocktitan.net/news/IMTX/immatics-annou...

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

3D illustration of aggressive cancer cells spreading in tissue, symbolizing advanced-stage disease targeted by innovative biotech treatments from Immatics N.V.

#Immatics (Nasdaq: #IMTX) presented new data at #ASCO25 showing encouraging results in metastatic melanoma patients treated with its experimental cell therapy.

prismmarketview.com/immatics-rep...

StockTitan

@stocktitan.net

9 months ago

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma Immatics presented extended Phase 1b trial data for IMA203 PRAME cell therapy at ASCO 2025, showing strong efficacy in metastatic melanoma patients. The trial of 33 heavily pretreated patients demonstrated a 56% confirmed objective response rate (cORR) and median duration of response of 12.1 months. Notably, cutaneous melanoma patients showed 50% cORR with duration not reached, while uveal melanoma patients achieved 67% cORR with 11-month duration. The therapy maintained a favorable safety profile, with manageable cytokine release syndrome and low neurotoxicity. Based on these positive results and PRAME's high prevalence in melanoma (90-95%), Immatics is advancing IMA203 in the Phase 3 SUPRAME trial for previously treated cutaneous melanoma patients, with BLA submission targeted for Q1 2027.

#IMTX Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

www.stocktitan.net/news/IMTX/immatics-ima20...

StockTitan

@stocktitan.net

10 months ago

Immatics Announces First Quarter 2025 Financial Results and Business Update Immatics (NASDAQ: IMTX) reported Q1 2025 financial results and provided updates on its PRAME-targeted cancer immunotherapy programs. The company's lead candidate, IMA203 PRAME cell therapy, is advancing in the Phase 3 SUPRAME trial for melanoma, with enrollment expected to complete in 2026. Immatics maintains a strong financial position with $588.1 million in cash and equivalents, providing runway into 2H 2027. Key developments include FDA IND clearance for a combination trial with Moderna's PRAME therapy and ongoing trials for multiple product candidates. The company reported a net loss of $43.2 million for Q1 2025, compared to $2.4 million in Q1 2024, primarily due to lower revenue and forex losses. R&D expenses increased to $45.3 million from $34.7 million year-over-year, reflecting advancement in clinical trials. The company will present updated IMA203 melanoma data at the 2025 ASCO Annual Meeting.

#IMTX Immatics Announces First Quarter 2025 Financial Results and Business Update

www.stocktitan.net/news/IMTX/immatics-annou...

StockTitan

@stocktitan.net

10 months ago

Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025 Latest IMA203 TCR T-cell therapy data for melanoma patients reveals extended follow-up outcomes and Phase 3 trial progress. Get exclusive ASCO insights.

#IMTX Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

www.stocktitan.net/news/IMTX/immatics-annou...

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

Small-cap stocks with declining money flow, Wed Apr 16th - #WNW #TRST #QRHC #WTI #SHCO #NVRO #MAX #KLC #FRGE #DTC #ZD #VREX #SCLX #ADVM #CADL #DOYU #GREE #IMTX #KIDS #PDLB - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

11 months ago

Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances Phase 1b melanoma therapy shows promising 12.1-month response duration. $628M cash runway supports Phase 3 trial advancement. See complete clinical data analysis.

#IMTX Immatics Announces Full Year 2024 Financial Results and Business Update

www.stocktitan.net/news/IMTX/immatics-annou...

StockTitan

@stocktitan.net

1 year ago

#IMTX Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

www.stocktitan.net/news/IMTX/immatics-annou...

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #IMTX ) Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #IMTX ) Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #IMTX ) (IMTX) On The My Stocks Page

#StockMarket #News